

November 12, 2021

BrightPath to Present Updates on the Pre-clinical Data of BP1210 at SITC 2021

*Presentations highlight significant new data for key oncology antibody development
- BP1210, anti-TIM-3 biparatopic antibody*

Tokyo, Japan – November 12, 2021/ -- BrightPath Biotherapeutics (TSE Mothers: 4594.T, “BrightPath”), a clinical-stage biotech company dedicated to the discovery and development of novel immunotherapies, today announced data presentations from its immuno-oncology pipeline at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021, November 12-14, Washington, D.C). The abstract featuring data on a anti-TIM-3 antibody, BP1210 will be shared in a poster viewing session.

“We have developed BP1210, a new TIM-3-targeting antibody that exploits the properties of TIM-3 protein domains and the interaction of TIM-3 to it’s multiple ligands. This antibody shows excellent efficacy in the activation of T cells and DCs with remarkable tumor cytotoxicity observed. We are excited to share this data at the 2021 SITC Annual Meeting and the potential of this novel engineered antibody for the treatment of solid tumor indications.” commented Kenichi Nagai, CEO of BrightPath.

Details of the presentation are as follows:

Title: Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity.

Authors: Yuji Mishima, Ph.D., Principal Scientist, Discovery Pharmacology at BrightPath Biotherapeutics

Poster Number: #235

Date & Time: November 12-13, 2021 (7:00 a.m. – 8:30 p.m. EST)

More detailed results will be shared as a poster presentation on the websites of [SITC](#) and [BrightPath](#) once the conference begins on November 12 at 7:00 a.m. EST.

About BP1210:

BP1210 is a humanized, anti-TIM-3 antibody that is designed to simultaneously binds to two distinct domains of TIM-3 protein. TIM-3 has multiple ligands including phosphatidylserine (PS) and galectin-9, which bind to different regions on TIM-3 and distinctively deactivate the function of immune cells involved in tumor immunity. However, anti-TIM-3 antibodies so far in clinical development had the capacity to interfere with PS binding but not galectin-9 binding to TIM-3 because of their epitope specificity of antibodies. BP1210 is an Fc-engineered, biparatopic antibody designed to block the interaction of the multiple ligands to TIM-3. The bivalent binding

to a single molecule of TIM-3 protein also confers high affinity and specificity to the target on the antibody, therefore, BP1210 effectively abrogate the T cell suppression to attack the tumor. BP1210 in combination with other suppressive immune pathways such as PD-1/PD-L1, is a key strategy to enhance the anti-tumor cytotoxic potential of immunotherapy.

About BrightPath:

BrightPath Biotherapeutics is an immuno-oncology focused biotech company dedicated to improving treatment and clinical outcomes for patients through cancer vaccine, therapeutic antibodies, and cell therapy that harness the immune system to fight cancer.

BrightPath's clinical-stage product, GRN-1201 is a new cancer vaccine in phase 2 trial in patients with melanoma and lung cancer in US. BP2201 in-collaboration with RIKEN, Japan is an iPS (induced pluripotent stem cell)-derived NKT therapy and the phase 1 trial is currently ongoing in Japan.

BrightPath's broad pipeline of immunotherapy includes several potentially first-in-class and best-in-class clinical and preclinical candidates in cancers with high unmet medical need.

BrightPath has been a pioneer in immunotherapy by cancer vaccine and has expanded its expertise in the tumor microenvironment and immune cell development as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio of cancer vaccine, therapeutic antibody, and immune-cell therapy.

Based in Tokyo, Japan, BrightPath is listed on Tokyo Stock Exchange in Japan. For more information, visit www.brightpathbio.com.

Forward-Looking Statements:

This news release contains forward-looking statements that are based on the current expectations and beliefs of BrightPath. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. BrightPath cautions that these forward-looking statements do not guarantee our future financial results but involve risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. These forward-looking statements speak only as of the date of this press release and BrightPath assumes no duty to update forward-looking statements, except as may be required by law.

Investor and Media Contact:

Takashi Hamamoto
Director of Corporate Management
+81-3-5840-7697
irpr@brightpathbio.com
www.brightpathbio.com